Skip Navigation
Skip to contents

ACC : Acute and Critical Care

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > Acute Crit Care > Volume 38(2); 2023 > Article
Original Article
Pulmonary Relationship between positive end-expiratory pressure levels, central venous pressure, systemic inflammation and acute renal failure in critically ill ventilated COVID-19 patients: a monocenter retrospective study in France
Pierre Basse1orcid, Louis Morisson2orcid, Romain Barthélémy1orcid, Nathan Julian1orcid, Manuel Kindermans1orcid, Magalie Collet1orcid, Benjamin Huot1orcid, Etienne Gayat1,3orcid, Alexandre Mebazaa1,3orcid, Benjamin G. Chousterman1,3orcid
Acute and Critical Care 2023;38(2):172-181.
DOI: https://doi.org/10.4266/acc.2022.01494
Published online: May 25, 2023

1Department of Anesthesiology and Critical Care Medicine, AP-HP, Hôpital Lariboisière, Paris, France

2Department of Anesthesiology and Pain Medicine, Hôpital Maisonneuve-Rosemont, CIUSSS de l’Est de l’Ile de Montréal, Montréal, QC Canada

3Université Paris-Cité, INSERM, U942 MASCOT, Paris, France

Corresponding author: Benjamin G. Chousterman Université Paris-Cité, APHP, CHU Lariboisière, Department of Anesthesia and Critical Care Medicine, 2 rue Ambroise Paré, Paris, France Tel: +33-1-4-95-85-15 Email: Benjamin.chousterman@aphp.fr
• Received: December 2, 2022   • Revised: February 7, 2023   • Accepted: February 10, 2023

Copyright © 2023 The Korean Society of Critical Care Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 3,290 Views
  • 96 Download
  • 1 Web of Science
  • 1 Crossref
  • 1 Scopus
prev next
Full Article

Download PDF Download PDF

  • Background
    The role of positive pressure ventilation, central venous pressure (CVP) and inflammation on the occurrence of acute kidney injury (AKI) have been poorly described in mechanically ventilated patient secondary to coronavirus disease 2019 (COVID-19).
  • Methods
    This was a monocenter retrospective cohort study of consecutive ventilated COVID-19 patients admitted in a French surgical intensive care unit between March 2020 and July 2020. Worsening renal function (WRF) was defined as development of a new AKI or a persistent AKI during the 5 days after mechanical ventilation initiation. We studied the association between WRF and ventilatory parameters including positive end-expiratory pressure (PEEP), CVP, and leukocytes count.
  • Results
    Fifty-seven patients were included, 12 (21%) presented WRF. Daily PEEP, 5 days mean PEEP and daily CVP values were not associated with occurrence of WRF. 5 days mean CVP was higher in the WRF group compared to patients without WRF (median [IQR], 12 mm Hg [11-13] vs. 10 mm Hg [9–12]; P=0.03). Multivariate models with adjustment on leukocytes and Simplified Acute Physiology Score (SAPS) II confirmed the association between CVP value and risk of WRF (odd ratio, 1.97; 95% confidence interval, 1.12–4.33). Leukocytes count was also associated with occurrence of WRF in the WRF group (14 G/L [11–18]) and the no-WRF group (9 G/L [8–11]) (P=0.002).
  • Conclusions
    In mechanically ventilated COVID-19 patients, PEEP levels did not appear to influence occurrence of WRF. High CVP levels and leukocytes count are associated with risk of WRF.
  • Keywords: acute kidney injury; central venous pressure; COVID-19; inflammation; positive end-expiratory pressure
Acute kidney injury (AKI) is a frequent complication among patient hospitalized for coronavirus disease 2019 (COVID-19) [1], with a wide range of incidence reported since the beginning of the epidemic, from 0.5% [2] to 36.6% [3]. Recently, a systematic review estimated the incidence around 10% among patient hospitalized for COVID-19 [4]. In critically ill patients, the incidence of AKI has been reported between 26% and 56% [4-6] and may be associated with severe complications such as the use of renal replacement therapy [7], progression of chronic kidney disease [8], and a higher rate of hospital mortality [9,10].
Pathophysiology of AKI in patients hospitalized in intensive care unit (ICU) for COVID 19 acute respiratory distress syndrome (ARDS) is multifactorial. Virus may exert a direct role on the renal parenchyma, by infecting the cells that express angiotensin-converting enzyme 2 (ACE-2) receptors [11] (podocytes and proximal tubular cells [12]). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes an increase in ACE activity and an overproduction of angiotensin II, leading to a proinflammatory state damaging the kidney [13]. It can also have an effect on glomerular cells [14], with collapsing glomerulopathy [15]. In addition, COVID-19 can lead to elevated levels of inflammatory cytokines, which can cause endothelial dysfunction, microvascular thrombosis and tubular cells damages [16]. Besides, hemodynamic consequences of ventilatory support (i.e., mechanical ventilation with positive pressure) could also directly impact glomerular function. Positive pressure ventilation has been shown to decreases renal blood flow, glomerular filtration rate, urine output, excretion of creatinine and sodium [17,18]. Previous studies has shown that elevated central venous pressure (CVP) is associated with AKI occurrence in ICU, especially in septic shock patients [19,20], suggesting a crucial role of the venous congestion in the development of AKI. By increasing intra thoracic and CVP, positive end-expiratory pressure (PEEP) level could have a direct impact on renal perfusion and occurrence of AKI [21].
The objective of the study was to investigate the relationship between hemodynamics, ventilatory parameters and systemic inflammation, and the progression of AKI in COVID-19 patients who required mechanical ventilation.
Study Design
We conducted a single center, retrospective cohort study in a 43 beds ICU in France during the COVID-19 surge. This study was approved by Institutional Review Board of Paris 7 University (No. 00006477, HUPNVS). Informed consent was waived by the board.
Patient Population
All patients admitted in ICU from March 2020 to July 2020 for a SARS-CoV-2 pneumoniae were screened. SARS-CoV-2 pneumoniae was defined by the association of evocative lung lesions seen in computed tomography scan or thoracic radiography and a positive polymerase chain reaction result for SARS-CoV-2. Patients were included if they were 18 years old or older and if they required mechanical ventilation for respiratory support during ICU stay. Patients were excluded if they were mechanically ventilated for another reason than respiratory failure, and if another diagnosis than SARS-CoV-2 was possible to explain the lung injury. Patients were also excluded if they had an AKI due to another disease than SARS-CoV-2 pneumoniae during the 3 days before admission to ICU.
Data Collection
Collected data were extracted from electronic and paper medical records. Day 1 was defined as the first day of mechanical ventilation. Demographic data included age, sex, comorbidities, treatment by renin angiotensin inhibitor, immunosuppressive therapy, use of corticosteroids, antiplatelet drug or anticoagulant therapy. Charlson comorbidity index, Simplified Acute Physiology Score (SAPS) II and Sequential Organ Failure Assessment (SOFA) scores [22,23] were calculated 24 hours after admission in ICU. Biological parameters included serum creatinine, urea, leukocytes count, neutrophils count, lymphocytes count, oxygen partial pressure in arterial blood.
Ventilatory and hemodynamic parameters included PEEP, plateau pressure, tidal volume, fraction of inspired oxygen and CVP and correspond to the mean values of the day (4–6 measurements every day for each parameter). According to local nursing monitoring protocols, plateau pressure reported in the medical records were the values of pressure displayed by the ventilator after a 5 seconds inspiratory pause. Criteria for ARDS were evaluated according to Berlin consensus [24]. Diuresis and daily fluid balance measured every day at the same hour were collected.
Patient Management
All patients were managed according to local protocol based on international guidelines. Respiratory management included limitation of tidal volume to 6 ml/kg, limitation of plateau and driving pressure, use of neuromuscular blockade and prone positioning session of at least 16 hours if necessary. PEEP levels were individualized according to a local protocol to improve oxygenation without deteriorating compliance and cardiac output. Patent foramen ovale and pleural effusions were systematically looked for and considered for drainage.
Hemodynamics optimizations were performed using cardiac output monitors for all patients, principally esophageal Doppler. Central line in the superior venous territory and arterial lines were inserted in all patients. CVP was measured continuously.
Definitions
The diagnosis of AKI was based on the Kidney Disease Improving Global Outcome (KDIGO) classification [25]. Severe AKI at admission was defined as an increase in serum creatinine level ≥2 times from baseline or ≥353.6 µmol/L or initiation of RRT corresponding to KDIGO stage 2 and 3. Baseline serum creatinine levels were measured in blood samples taken before hospital admission when available. When baseline creatinine was not available, the lowest serum creatinine level measured during the patient’s hospital stay was used if the glomerular filtration rate calculated with Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula was ≥75 mL/min/1.73m2. In other cases, the baseline creatinine level was estimated by using the modification of diet in renal disease equation with the assumption of an age-adjusted glomerular filtration rate because this approach performed best in terms of generating the smallest number of false negatives [26].
New, persistent and transient AKI
New severe AKI was defined as an increase in serum creatinine level ≥2 times from baseline or ≥353.6 µmol/L or initiation of RRT after 24 hours from inclusion in patients who had no severe AKI upon the initiation of mechanical ventilation (MV). Persistent severe AKI was defined as a steady or increase in KDIGO classification stage between the first 24 hours following initiation of MV and day 5 in patients with KDIGO stage ≥2 at inclusion or between the first 24 hours following initiation of MV and the last day of MV depending on which one comes first. Transient severe AKI was defined as a resolution or a downstaging of AKI between the first 24 hours following inclusion and day 5 (example from KDIGO stage 2 to KDIGO stage 1).
Worsening renal function
Worsening renal function (WRF) was defined as a new or persistent severe AKI (WRF+). Patients with no AKI or transient severe AKI were considered as patient without WRF (WRF–).
Primary endpoint
The primary endpoint of the study was to investigate the relationship between PEEP, CVP and WRF during the 5 days following the initiation of mechanical ventilation.
Secondary endpoints
The secondary endpoint was to identify other risk factors associated with WRF.
Statistical Analysis
Quantitative parameters are reported as median with interquartile range (IQR) and qualitative parameters are expressed as number and percentage. Categorical variables were compared using Fisher exact test as appropriate. Continuous variables were compared using Mann-Whitney U-test.
Actualized mean PEEP was defined by the cumulative mean PEEP dose, i.e., the mean PEEP between the day studied and the previous day. We also calculated mean values during 5 days for the daily PEEP, CVP, leukocytes count, and neutrophils count to reflect the overall exposition of the kidney, to elevated pressures and inflammation during the first days of mechanical ventilation.
We developed two multivariable models with adjustment for cofounding factors (SAPS II and mean leukocytes count for 5 days) to assess the association between mean CVP level for 5 days, mean PEEP level for 5 days and the risk of WRF. Predicted probabilities of WRF by the models were plotted together with significantly associated variables and a local polynomial regression fitting was performed to visually assess the relationship between the variable and the risk of WRF.
Finally, the relationship between PEEP level and CVP was explored using linear regression. A P-value lower than 0.05 has been considered significant. Odds ratio are reported with 95% confidence intervals (CIs). All statistical analyses were performed using R statistical software version 4.0.2 (R Core Team, 2020, R Foundation for Statistical Computing; https://www.R-project.org).
Baseline Characteristics
Seventy-three patients with SARS-CoV-2 pneumoniae were screened. Among them, 57 were mechanically ventilated and included in the study. All patients fulfilled Berlin criteria for ARDS. Flowchart is shown in Supplementary Figure 1.
Among the 57 included patients severe AKI was diagnosed in 16 patients (28%). Severe AKI was diagnosed at the time of intubation in 11 patients (19.3%). Among them, four patients presented a transient AKI, and seven patients had a persistent severe AKI. Forty-six patients (80.7%) had no severe AKI at the time of intubation, five developed a new severe AKI. Therefore, 12 patients were included in the WRF+ and 45 patients were included in the WRF– group.
Baseline characteristics are shown in Table 1. Patients in the WRF+ group were mainly females and had higher SOFA and SAPS II scores. They were more susceptible to have hypertension and a pre-existing chronic kidney failure. Leukocytes at admission were higher in the WRF+ group than in the WRF– group (median [IQR], 12 [11–14] vs. 9 [7–11]; P=0.01). Regarding the ventilatory parameters at day 1, there was no difference of ratio between the partial pressure in O2 and the inspiratory fraction of O2 (P/F ratio), PEEP, compliance, Pplat and inspiratory fraction of oxygen between groups. The CVP was also not different between groups at the time of intubation.
Concerning the need for vasopressors, there was no difference in terms of the number of patients requiring vasopressors between the WRF– and WRF+ group (35 [81.4%] vs. 12 [100.0%], P=0.249). There was also no difference in terms of the vasopressors free days during the 5 days post intubation between the WRF– and WRF+ groups (median [IQR], 2 [0–4] vs. 1 [0–2]; P=0.13).
Association between AKI and Ventilatory Parameters
During the 5 days following the initiation of mechanical ventilation, there was no difference in daily compliance, daily PEEP and daily actualized mean PEEP between groups except for PEEP and actualized mean PEEP at day 2 (Figure 1, Supplementary Figures 2 and 3). The PEEP mean value during the 5 days was not different between the WRF+ and WRF–groups (median [IQR], 10 [9–11] vs. 8 [8–11]; P=0.09) (Table 2). The absence of association between PEEP and WRF persisted after multivariable analysis (Supplementary Table 1, Supplementary Figure 4).
Association between Ventilatory Parameters, CVP and AKI
The daily values of CVP were not different between the two groups (Supplementary Figure 5). However, the mean value of CVP within 5 days after intubation was more elevated in the WRF+ group than in the WRF–group (median [IQR], 12 [11–13] vs. 10 [9–12]; P=0.03) (Table 2). Using multivariable analysis, there was a positive relationship between mean values of CVP during the 5 days and the risk of WRF, with an odd ratio for WRF of 1.97 (95% CI, 1.12–4.33) per increase of 1 mm Hg of CVP (Supplementary Table 2), and a significant increase in risk of WRF with CVP values above 10 mm Hg (Figure 2). Investigating the relationship between PEEP and venous pressure, there was a linear relationship between PEEP level and CVP (Figure 3).
Association between AKI and Biological Parameters
Daily leukocytes and neutrophils were more elevated in the WRF+ group (Figure 4, Supplementary Figure 6), except for neutrophils on the day 4. The mean value of leukocytes on the 5 days after intubation were 14 G/L (IQR, 11–18) in the WRF+ group and 9 G/L (IQR, 8–11) in the WRF– group (P=0.002), and mean value of neutrophils were also higher in the WRF+ group (11 G/L [IQR, 10–15]) than in the WRF– group (8 G/L [IQR, 6–9]) (P=0.001). We did not observe any difference in lymphocytes count between the two groups (Supplementary Figure 7).
In the present study, we found no association between PEEP levels and WRF. CVP levels are associated with the risk of WRF, especially above 10 mm Hg. PEEP may be associated with WRF through its impact on CVP. Inflammation also seems to be a contributor to WRF. The relationship between PEEP and AKI has been evoked multiple times in the literature [27-30]. Anyway, few studies investigated the impact of PEEP levels on occurrence or persistence of AKI to date. The COVID-19 pandemic recently emphasized the major importance of adequate ventilator management of ARDS patients. We showed that PEEP has a dramatic impact on global hemodynamics and may reduce oxygen delivery while improving P/F ratio [31].
The contribution of right side pressure, i.e. CVP, to AKI has been well described [19,20]. A strength of our study is to investigate together PEEP and CVP impact on AKI. The global impact of PEEP on CVP is uncertain [32-34] and relies on various factors (hypovolemia, compliance, right heart function, etc.). It has been proven that PEEP increases CVP, although it is impossible to predict the raise in patients with altered lung compliance. It is therefore consistent with physiology and physiological studies to find an elevation of the PVC level with PEEP level. In our study, CVP levels increases with peep levels, but PEEP levels did not differ between patient with or without WRF. Consistently with literature [21], we found an increased risk of WRF with high values of CVP (above 10 mm Hg). These results highlight the fact that PEEP may contribute to occurrence of WRF through its impact on CVP. Therefore, ventilatory and hemodynamic management of COVID-19 ARDS patients should focus on the evolution of CVP in order to prevent kidney injury. Interestingly, we found that inflammation was a risk factor of WRF. One study has recently found that high neutrophils count in ICU was associated with severe AKI [35]. Our results support the hypothesis of a role of inflammation in case of AKI in COVID 19. Thus, management of the inflammatory part of AKI relies on the control of the disease and may respond to immunomodulatory treatments that were recently put under the light with the pandemic.
In the present study, we decided to consider both new AKI and persistent AKI together. This concept of WRF fits well with ICU daily practice. Indeed, a large proportion of AKI occurs before ICU admission [36]. It seems adequate to consider that the same factors contribute to both development and persistence of AKI.
Our study suffers several limitations. First, the retrospective, single center, nature of our study may prevent us generalizing our results. However, our center is expert in hemodynamic monitoring, with a trained and experienced team, implying that the CVP values reported can be considered reliable. More, all the patients were treated homogeneously, with local protocols in accordance with international guidelines [37].
Second, there were several imbalances between the two groups, and not every variables were taken into account in the analyses, likely due to the limited number of patients. Third, the CVP levels reported were relatively low. This can be explained by the fact that our teams is concerned about maintaining low CVP, in order to limit the repercussions of subsequent right side heart failure. Last, this study was conducted during the first wave of COVID 19, implying that none of these patients received immunomodulatory therapy such as dexamethasone or tocilizumab. In addition, some of these patients did not immediately benefit from enhanced preventive anticoagulation as recommended now [38].
Based on these results, it appears that kidney protection should be an objective of the ventilatory strategy. In mechanically ventilated COVID-19 patients, PEEP level did not appear to influence occurrence of WRF, high CVP levels and leukocytes count are associated with risk of WRF.
▪ In acute respiratory distress syndrome due to coronavirus disease 2019 (COVID-19), patients with high central venous pressure and high leucocytes count had a higher risk of acute kidney injury.
▪ Positive pressure expiratory levels did not appear to influence occurrence of acute kidney injury .
▪ These results suggest a major role of central venous pressure and inflammation on occurrence of acute kidney injury among patients ventilated for severe COVID-19.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

FUNDING

None.

AUTHOR CONTRIBUTIONS

Conceptualization: PB, AM, BGC. Data curation: PB, BGC. Formal analysis: LM, BH. Methodology: EG, AM. Visualization: LM, RB, EG. Writing–original draft: PB, RB, NJ, MK, MC, BGC. Writing–review & editing: PB, BGC.

None.
Supplementary materials can be found via https://doi.org/10.4266/acc.2022.01494.
Supplementary Table 1.
Multivariate model including 5 days mean PEEP, 5 days mean leukocytes and SAPS II for the prediction of worsening renal function
acc-2022-01494-Supplementary-Table-1.pdf
Supplementary Table 2.
Multivariate model including 5 days mean CVP, 5 days mean leukocytes and SAPS II for the risk of worsening renal function
acc-2022-01494-Supplementary-Table-2.pdf
Supplementary Figure 1.
Flowchart. WRF: worsening renal function; COVID-19: coronavirus disease 2019; AKI: acute kidney injury.
acc-2022-01494-Supplementary-Fig-1.pdf
Supplementary Figure 2.
Comparison of daily actualized mean positive end expiratory pressure (PEEP) during the 5 days following intubation.
acc-2022-01494-Supplementary-Fig-2.pdf
Supplementary Figure 3.
Comparison of daily compliance during the 5 days following intubation.
acc-2022-01494-Supplementary-Fig-3.pdf
Supplementary Figure 4.
Risk of worsening renal function according to the mean value of positive end expiratory pressure (PEEP) value.
acc-2022-01494-Supplementary-Fig-4.pdf
Supplementary Figure 5.
Comparison of daily central venous pressure during the 5 days following intubation.
acc-2022-01494-Supplementary-Fig-5.pdf
Supplementary Figure 6.
Comparison of daily neutrophils during the 5 days following intubation.
acc-2022-01494-Supplementary-Fig-6.pdf
Supplementary Figure 7.
Comparison of daily lymphocytes during the 5 days following intubation.
acc-2022-01494-Supplementary-Fig-7.pdf
Figure 1.
Comparison of daily positive end expiratory pressure (PEEP) during the 5 days following intubation.
acc-2022-01494f1.jpg
Figure 2.
Risk of worsening renal function according to the mean value of central venous pressure during the 5 days.
acc-2022-01494f2.jpg
Figure 3.
Relationship between central venous pressure and positive end expiratory pressure (PEEP).
acc-2022-01494f3.jpg
Figure 4.
Comparison of daily leukocytes during the 5 days following intubation.
acc-2022-01494f4.jpg
Table 1.
Demographic characteristics
Variable WRF– WRF+ Total P-value  
Number of patients 45 12 57 -
Age (yr) 60 (54–66) 64 (53–70) 62 (54–67) 0.35
Male 41 (91.1) 7 (58.3) 48 (84.2) 0.02
Chronic hypertension 17 (38.6) 10 (83.3) 27 (47.4) 0.02
Diabetes 17 (38.6) 6 (50.0) 23 (40.4) 0.70
Tobacco use 3 (7) 0 3 (5.3) 0.57
Chronic cardiovascular disease 7 (15.9) 2 (18.2) 9 (15.8) 1.00
Chronic lung disease 9 (20.9) 3 (27.3) 12 (21.1) 1.00
Chronic kidney disease 4 (9.3) 5 (45.5) 9 (15.8) 0.02
Renin–angiotensin–aldosterone system inhibitor therapy 13 (29.5) 8 (72.7) 21 (36.8) 0.02
Corticosteroid therapy 0 0 0 -
Immunosuppressants 1 (2.3) 2 (18.2) 3 (5.3) 0.18
Antiplatelet therapy 9 (20.5) 2 (18.2) 11 (19.3) 1.00
Anticoagulant therapy 0 1 (9.1) 1 (1.8) 0.44
SAPS II at admission 41 (31–49) 52 (46–63) 42 (33–53) 0.05
SOFA score at admission 7 (5–9) 11 (10–13) 7 (6-10) 0.001
Charlson comorbidity index 2 (1–3) 3 (2–4) 2 (1–4) 0.12
Creatinine (µmol/L) 86 (64–109) 227 (102–335) 89 (69–129) 0.001
Urea (mmol/L) 6.2 (4.4–9.8) 17.3 (9.6–20.6) 6.9 (4.8–12) 0.003
Leukocytes (G/L) 9 (7–11) 12 (11–15) 10 (7–12) 0.01
Neutrophils (G/L) 7 (6–10) 11 (10–12) 8 (6–10) 0.01
Lymphocytes (G/L) 0.8 (0.6–1.1) 1.2 (0.6–1.3) 0.9 (0.6–1.0) 0.33
Use of vasopressors 30 (68.2) 11 (91.7) 41 (71.9) 0.20
CVP (mm Hg) 9 (7–11) 11 (10–12) 10 (7–12) 0.01
PEEP (cm H2O) 8 (8–10) 9 (8–12) 8 (8–10) 0.21
P/F ratio 121 (70–223) 108 (84–166) 117 (71–194) 0.59
Compliance (ml/cm H2O) 28 (25–37) 34 (28–37) 30 (25–37) 0.32
Plateau pressure (cm H2O) 24 (22–26) 25 (23–26) 24 (22–26) 0.64

Values are presented as median (interquartile range) or number (%).

WRF: worsening renal function; WRF-: patients without WRF; WRF+: patients with a new or per­sistent severe acute kidney injury; SAPS: Simplified Acute Physiology Score; SOFA: Sequential Organ Failure Assessment; CVP: central venous pressure; PEEP: positive end expiratory pressure; P/F ratio: ratio between the partial pressure in O2 and the inspiratory fraction of O2.

Table 2.
Mean values of PEEP, P/F ratio, CVP, leukocytes, and neutrophils during the 5 days following intubation
Variable WRF– WRF+ P-value
Number of patients 45 12 -
Mean PEEP (cm H2O) 8 (8–11) 10 (9–11) 0.01
Mean P/F ratio 200 (155–246) 238 (167–257) 0.42
Mean CVP (mm Hg) 10 (9–12) 12 (11–13) 0.03
Mean leukocytes (G/L) 9 (8–11) 14 (11–18) 0.002
Mean neutrophils (G/L) 8 (6–9) 11 (10–15) 0.001

Values are presented as median (interquartile range).

PEEP: positive end expiratory pressure; P/F ratio: ratio between the partial pressure in O2 and the inspiratory; CVP: central venous pressure; WRF: worsening renal function; WRF-: patients without WRF; WRF+: patients with a new or per­sistent severe acute kidney injury .

  • 1. Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in hospitalized patients with COVID-19. J Am Soc Nephrol 2021;32:151-60.ArticlePubMed
  • 2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.ArticlePubMed
  • 3. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int 2020;98:209-18.ArticlePubMedPMC
  • 4. Xu Z, Tang Y, Huang Q, Fu S, Li X, Lin B, et al. Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with COVID-19. BMC Nephrol 2021;22:52. ArticlePubMedPMCPDF
  • 5. Chang R, Elhusseiny KM, Yeh YC, Sun WZ. COVID-19 ICU and mechanical ventilation patient characteristics and outcomes: a systematic review and meta-analysis. PLoS One 2021;16:e0246318.ArticlePubMedPMC
  • 6. Costa RL, Sória TC, Salles EF, Gerecht AV, Corvisier MF, Menezes MA, et al. Acute kidney injury in patients with Covid-19 in a Brazilian ICU: incidence, predictors and in-hospital mortality. J Bras Nefrol 2021;43:349-58.ArticlePubMedPMC
  • 7. Yang X, Tian S, Guo H. Acute kidney injury and renal replacement therapy in COVID-19 patients: a systematic review and meta-analysis. Int Immunopharmacol 2021;90:107159. ArticlePubMed
  • 8. Hultström M, Lipcsey M, Wallin E, Larsson IM, Larsson A, Frithiof R. Severe acute kidney injury associated with progression of chronic kidney disease after critical COVID-19. Crit Care 2021;25:37. ArticlePubMedPMCPDF
  • 9. Hamilton P, Hanumapura P, Castelino L, Henney R, Parker K, Kumar M, et al. Characteristics and outcomes of hospitalised patients with acute kidney injury and COVID-19. PloS One 2020;15:e0241544.ArticlePubMedPMC
  • 10. Doher MP, Torres de Carvalho FR, Scherer PF, Matsui TN, Ammirati AL, Caldin da Silva B, et al. Acute kidney injury and renal replacement therapy in critically ill COVID-19 patients: risk factors and outcomes: a single-center experience in Brazil. Blood Purif 2021;50:520-30.ArticlePubMedPDF
  • 11. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-80.ArticlePubMedPMC
  • 12. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020;14:185-92.ArticlePubMedPMCPDF
  • 13. Migliaccio MG, Di Mauro M, Ricciolino R, Spiniello G, Carfora V, Verde N, et al. Renal involvement in COVID-19: a review of the literature. Infect Drug Resist 2021;14:895-903.ArticlePubMedPMCPDF
  • 14. Batlle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, et al. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J Am Soc Nephrol 2020;31:1380-3.ArticlePubMedPMC
  • 15. Legrand M, Bell S, Forni L, Joannidis M, Koyner JL, Liu K, et al. Pathophysiology of COVID-19-associated acute kidney injury. Nat Rev Nephrol 2021;17:751-64.ArticlePubMedPMCPDF
  • 16. Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol 2021;93:250-6.ArticlePubMedPDF
  • 17. Mullins RJ, Dawe EJ, Lucas CE, Ledgerwood AM, Banks SM. Mechanisms of impaired renal function with PEEP. J Surg Res 1984;37:189-96.ArticlePubMed
  • 18. Priebe HJ, Heimann JC, Hedley-Whyte J. Mechanisms of renal dysfunction during positive end-expiratory pressure ventilation. J Appl Physiol Respir Environ Exerc Physiol 1981;50:643-9.ArticlePubMed
  • 19. Legrand M, Dupuis C, Simon C, Gayat E, Mateo J, Lukaszewicz AC, et al. Association between systemic hemodynamics and septic acute kidney injury in critically ill patients: a retrospective observational study. Crit Care 2013;17:R278. ArticlePubMedPMC
  • 20. Chen KP, Cavender S, Lee J, Feng M, Mark RG, Celi LA, et al. Peripheral edema, central venous pressure, and risk of AKI in critical illness. Clin J Am Soc Nephrol 2016;11:602-8.ArticlePubMedPMC
  • 21. Geri G, Ferrer L, Tran N, Celi LA, Jamme M, Lee J, et al. Cardio-pulmonary-renal interactions in ICU patients: role of mechanical ventilation, venous congestion and perfusion deficit on worsening of renal function: insights from the MIMIC-III database. J Crit Care 2021;64:100-7.ArticlePubMedPMC
  • 22. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-63.ArticlePubMed
  • 23. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.ArticlePubMedPDF
  • 24. ARDS Definition Task Force; Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307:2526-33.PubMed
  • 25. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012;120:c179-84.ArticlePubMedPDF
  • 26. Kork F, Balzer F, Krannich A, Bernardi MH, Eltzschig HK, Jankowski J, et al. Back-calculating baseline creatinine overestimates prevalence of acute kidney injury with poor sensitivity. Acta Physiol (Oxf) 2017;219:613-24.ArticlePubMedPDF
  • 27. Ottolina D, Zazzeron L, Trevisi L, Agarossi A, Colombo R, Fossali T, et al. Acute kidney injury (AKI) in patients with Covid-19 infection is associated with ventilatory management with elevated positive end-expiratory pressure (PEEP). J Nephrol 2022;35:99-111.ArticlePubMedPDF
  • 28. Beurton A, Haudebourg L, Simon-Tillaux N, Demoule A, Dres M. Limiting positive end-expiratory pressure to protect renal function in SARS-CoV-2 critically ill patients. J Crit Care 2020;59:191-3.ArticlePubMedPMC
  • 29. Chaibi K, Dao M, Pham T, Gumucio-Sanguino VD, Di Paolo FA, Pavot A, et al. Severe acute kidney injury in patients with COVID-19 and acute respiratory distress syndrome. Am J Respir Crit Care Med 2020;202:1299-301.ArticlePubMedPMC
  • 30. van den Akker JP, Egal M, Groeneveld AB. Invasive mechanical ventilation as a risk factor for acute kidney injury in the critically ill: a systematic review and meta-analysis. Crit Care 2013;17:R98. ArticlePubMedPMC
  • 31. Barthélémy R, Beaucoté V, Bordier R, Collet M, Le Gall A, Hong A, et al. Haemodynamic impact of positive end-expiratory pressure in SARS-CoV-2 acute respiratory distress syndrome: oxygenation versus oxygen delivery. Br J Anaesth 2021;126:e70-2.ArticlePubMed
  • 32. Gelman S. Venous function and central venous pressure: a physiologic story. Anesthesiology 2008;108:735-48.PubMed
  • 33. Vieillard-Baron A, Matthay M, Teboul JL, Bein T, Schultz M, Magder S, et al. Experts’ opinion on management of hemodynamics in ARDS patients: focus on the effects of mechanical ventilation. Intensive Care Med 2016;42:739-49.ArticlePubMedPDF
  • 34. Jardin F, Vieillard-Baron A. Right ventricular function and positive pressure ventilation in clinical practice: from hemodynamic subsets to respirator settings. Intensive Care Med 2003;29:1426-34.ArticlePubMedPDF
  • 35. Hardenberg JB, Stockmann H, Aigner A, Gotthardt I, Enghard P, Hinze C, et al. Critical illness and systemic inflammation are key risk factors of severe acute kidney injury in patients with COVID-19. Kidney Int Rep 2021;6:905-15.ArticlePubMedPMC
  • 36. Lumlertgul N, Pirondini L, Cooney E, Kok W, Gregson J, Camporota L, et al. Acute kidney injury prevalence, progression and long-term outcomes in critically ill patients with COVID-19: a cohort study. Ann Intensive Care 2021;11:123. ArticlePubMedPMCPDF
  • 37. Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med 2014;40:1795-815.ArticlePubMedPMCPDF
  • 38. Susen S, Tacquard CA, Godon A, Mansour A, Garrigue D, Nguyen P, et al. Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Crit Care 2020;24:364. ArticlePubMedPMCPDF

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Bidirectional pressure: a mini review of ventilator-lung-kidney interactions
      Avnee Kumar, Katie Epler, Sean DeWolf, Laura Barnes, Mark Hepokoski
      Frontiers in Physiology.2024;[Epub]     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Relationship between positive end-expiratory pressure levels, central venous pressure, systemic inflammation and acute renal failure in critically ill ventilated COVID-19 patients: a monocenter retrospective study in France
      Acute Crit Care. 2023;38(2):172-181.   Published online May 25, 2023
      DOI: https://doi.org/10.4266/acc.2022.01494
      Close
    • XML DownloadXML Download
    Figure
    • 0
    • 1
    • 2
    • 3
    Relationship between positive end-expiratory pressure levels, central venous pressure, systemic inflammation and acute renal failure in critically ill ventilated COVID-19 patients: a monocenter retrospective study in France
    Image Image Image Image
    Figure 1. Comparison of daily positive end expiratory pressure (PEEP) during the 5 days following intubation.
    Figure 2. Risk of worsening renal function according to the mean value of central venous pressure during the 5 days.
    Figure 3. Relationship between central venous pressure and positive end expiratory pressure (PEEP).
    Figure 4. Comparison of daily leukocytes during the 5 days following intubation.

    Figure 1.

    Figure 2.

    Figure 3.

    Figure 4.

    Relationship between positive end-expiratory pressure levels, central venous pressure, systemic inflammation and acute renal failure in critically ill ventilated COVID-19 patients: a monocenter retrospective study in France
    Variable WRF– WRF+ Total P-value  
    Number of patients 45 12 57 -
    Age (yr) 60 (54–66) 64 (53–70) 62 (54–67) 0.35
    Male 41 (91.1) 7 (58.3) 48 (84.2) 0.02
    Chronic hypertension 17 (38.6) 10 (83.3) 27 (47.4) 0.02
    Diabetes 17 (38.6) 6 (50.0) 23 (40.4) 0.70
    Tobacco use 3 (7) 0 3 (5.3) 0.57
    Chronic cardiovascular disease 7 (15.9) 2 (18.2) 9 (15.8) 1.00
    Chronic lung disease 9 (20.9) 3 (27.3) 12 (21.1) 1.00
    Chronic kidney disease 4 (9.3) 5 (45.5) 9 (15.8) 0.02
    Renin–angiotensin–aldosterone system inhibitor therapy 13 (29.5) 8 (72.7) 21 (36.8) 0.02
    Corticosteroid therapy 0 0 0 -
    Immunosuppressants 1 (2.3) 2 (18.2) 3 (5.3) 0.18
    Antiplatelet therapy 9 (20.5) 2 (18.2) 11 (19.3) 1.00
    Anticoagulant therapy 0 1 (9.1) 1 (1.8) 0.44
    SAPS II at admission 41 (31–49) 52 (46–63) 42 (33–53) 0.05
    SOFA score at admission 7 (5–9) 11 (10–13) 7 (6-10) 0.001
    Charlson comorbidity index 2 (1–3) 3 (2–4) 2 (1–4) 0.12
    Creatinine (µmol/L) 86 (64–109) 227 (102–335) 89 (69–129) 0.001
    Urea (mmol/L) 6.2 (4.4–9.8) 17.3 (9.6–20.6) 6.9 (4.8–12) 0.003
    Leukocytes (G/L) 9 (7–11) 12 (11–15) 10 (7–12) 0.01
    Neutrophils (G/L) 7 (6–10) 11 (10–12) 8 (6–10) 0.01
    Lymphocytes (G/L) 0.8 (0.6–1.1) 1.2 (0.6–1.3) 0.9 (0.6–1.0) 0.33
    Use of vasopressors 30 (68.2) 11 (91.7) 41 (71.9) 0.20
    CVP (mm Hg) 9 (7–11) 11 (10–12) 10 (7–12) 0.01
    PEEP (cm H2O) 8 (8–10) 9 (8–12) 8 (8–10) 0.21
    P/F ratio 121 (70–223) 108 (84–166) 117 (71–194) 0.59
    Compliance (ml/cm H2O) 28 (25–37) 34 (28–37) 30 (25–37) 0.32
    Plateau pressure (cm H2O) 24 (22–26) 25 (23–26) 24 (22–26) 0.64
    Variable WRF– WRF+ P-value
    Number of patients 45 12 -
    Mean PEEP (cm H2O) 8 (8–11) 10 (9–11) 0.01
    Mean P/F ratio 200 (155–246) 238 (167–257) 0.42
    Mean CVP (mm Hg) 10 (9–12) 12 (11–13) 0.03
    Mean leukocytes (G/L) 9 (8–11) 14 (11–18) 0.002
    Mean neutrophils (G/L) 8 (6–9) 11 (10–15) 0.001
    Table 1. Demographic characteristics

    Values are presented as median (interquartile range) or number (%).

    WRF: worsening renal function; WRF-: patients without WRF; WRF+: patients with a new or per­sistent severe acute kidney injury; SAPS: Simplified Acute Physiology Score; SOFA: Sequential Organ Failure Assessment; CVP: central venous pressure; PEEP: positive end expiratory pressure; P/F ratio: ratio between the partial pressure in O2 and the inspiratory fraction of O2.

    Table 2. Mean values of PEEP, P/F ratio, CVP, leukocytes, and neutrophils during the 5 days following intubation

    Values are presented as median (interquartile range).

    PEEP: positive end expiratory pressure; P/F ratio: ratio between the partial pressure in O2 and the inspiratory; CVP: central venous pressure; WRF: worsening renal function; WRF-: patients without WRF; WRF+: patients with a new or per­sistent severe acute kidney injury .

    Table 1.

    Table 2.

    ACC : Acute and Critical Care
    © The Korean Society of Critical Care Medicine.
    TOP